Paracetamol β-D-Glucoside: Prodrug Design, Kinetics, and Regulatory Stability Assessment
Abstract
Many medicines do not dissolve well in water, which can limit how quickly and effectively they work. One proven way to improve this is to attach a natural sugar molecule to the drug. In this study, we investigate paracetamol β-D-glucoside (C14H19NO7), a modified form of paracetamol in which glucose is chemically linked to the drug through a β-glycosidic bond. This simple molecular change increases water solubility by 6–8 times compared to regular paracetamol, allowing faster dissolution and more flexible liquid formulations. The sugar–drug link is stable under normal body conditions but breaks apart under specific environments. At neutral pH (similar to blood), the compound remains highly stable, with a half-life exceeding 1000 hours at 25 ℃. Under acidic conditions similar to the stomach (pH 2, 37 ℃), it breaks down within minutes, releasing active paracetamol. Natural enzymes in the intestine and liver can also rapidly cleave the bond, enabling controlled and site-specific drug activation. Computer simulations confirm the proposed breakdown mechanism and support the experimental findings. Stability testing was performed under internationally recognised pharmaceutical guidelines (ICH, USP, FDA, EMA), showing predictable behaviour and acceptable impurity control. Formulation strategies such as protective coatings and temperature management suggest a projected shelf life of 2–3 years. Importantly, when the compound breaks down, it releases both paracetamol and a small amount…
Read the paper
Related studies
- Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial
- Effect of a Postoperative Multimodal Opioid-Sparing Protocol vs Standard Opioid Prescribing on Postoperative Opioid Consumption After Knee or Shoulder Arthroscopy: A Randomized Clinical Trial
- Comparison of the Post-Caesarean Analgesic Effect of Adding Dexmedetomidine to Paracetamol and Ketorolac: A Randomized Clinical Trial
- A triple-blind randomized clinical trial of different associations between dexamethasone and non-steroids anti-inflammatories for preemptive action in third molar extractions
- An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
- Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: Single centre double-blind, randomised controlled clinical trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.